{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-270961","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.113686+00:00","generated_at":"2026-06-23T00:37:56.838005+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ResMed Q1 FY23 revenue $950.3M (+5% YoY, +9% CC); GAAP EPS $1.43, non-GAAP $1.51","bullets":["Revenue $950.3M, up 5% YoY (9% constant currency); Americas (ex-SaaS) revenue up 18%.","GAAP operating profit $275.7M (+5%), non-GAAP operating profit $290.8M (+4%).","GAAP diluted EPS $1.43 vs $1.39; non-GAAP diluted EPS $1.51 flat YoY.","Board declared quarterly dividend $0.44/share, payable Dec 15, 2022, record Nov 10.","Acquired mementor (German digital sleep medicine); opened new R&D facility in Ireland."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-270961","json":"https://secwatch.observer/filing/0001193125-22-270961.json","markdown":"https://secwatch.observer/filing/0001193125-22-270961.md","text":"https://secwatch.observer/filing/0001193125-22-270961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312522270961/0001193125-22-270961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312522270961/d416189d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:37:56.838005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}